Arkolith/Insider Trading/RPHM/Form 4

Cruse Michael

Chief Operating OfficerReneo Pharmaceuticals, Inc. (RPHM) · full profile →Form 4 · filed Aug 31, 2022
Net Buying
Open-Market Buys
$23K
Open-Market Sells
$0
Net Open-Market Flow
$23K
Transactions
5
5 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 31, 2022Buy(P)3K$3.21$10K6K
Aug 30, 2022Buy(P)975$3.16$3K32K
Aug 30, 2022Buy(P)2K$3.19$6K3K
Aug 29, 2022Buy(P)83$3.24$26931K
Aug 29, 2022Buy(P)1K$3.24$4K1K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-22-048167) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML